Akers Biosciences Company Profile (LON:AKR)

About Akers Biosciences (LON:AKR)

Akers Biosciences logoAkers Biosciences, Inc. develops, manufactures and supplies point-of-care screening and testing products designed to bring health-related information to the patient or clinician. The Company's product offerings and pipeline products focus on delivering diagnostic assistance in a range of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious diseases detection, as well as for on and off-the-job alcohol safety initiatives. The Company's primary focus is the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company's main products include a disposable breathalyzer test that measures the blood alcohol content of the user, a rapid test detecting the antibody causing an allergic reaction to Heparin and a disposable breathalyzer test that measures Free Radical activity in the human body.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: LON:AKR
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: £9.96 million
  • Outstanding Shares: 8,853,000
Average Prices:
  • 50 Day Moving Avg: GBX 126.50
  • 200 Day Moving Avg: GBX 137.59
  • 52 Week Range: GBX 86 - GBX 255
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: £2.96 million
  • Price / Sales: 3.36
  • Book Value: GBX 0.62 per share
  • Price / Book: 1.81
Profitability:
  • EBIDTA: ($4,190,000.00)
Misc:
  • Average Volume: 2,608 shs.
 

Frequently Asked Questions for Akers Biosciences (LON:AKR)

What is Akers Biosciences' stock symbol?

Akers Biosciences trades on the London Stock Exchange (LON) under the ticker symbol "AKR."

Where is Akers Biosciences' stock going? Where will Akers Biosciences' stock price be in 2017?

0 brokers have issued twelve-month price targets for Akers Biosciences' stock. Their forecasts range from GBX 150 to GBX 150. On average, they anticipate Akers Biosciences' share price to reach GBX 150 in the next twelve months. View Analyst Ratings for Akers Biosciences.

Who are some of Akers Biosciences' key competitors?

How do I buy Akers Biosciences stock?

Shares of Akers Biosciences and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How much does a share of Akers Biosciences stock cost?

One share of Akers Biosciences stock can currently be purchased for approximately GBX 112.50.

Analyst Ratings

Consensus Ratings for Akers Biosciences (LON:AKR) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: GBX 150

Analysts' Ratings History for Akers Biosciences (LON:AKR)
Show:
DateFirmActionRatingPrice TargetDetails
5/16/2017FinnCapReiterated RatingCorporateView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Akers Biosciences (LON:AKR)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Akers Biosciences (LON:AKR)
Current Year EPS Consensus Estimate: $-0.30 EPS

Dividends

Dividend History for Akers Biosciences (LON:AKR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Akers Biosciences (LON:AKR)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Akers Biosciences (LON:AKR)
Latest Headlines for Akers Biosciences (LON:AKR)
Source:
DateHeadline
finanznachrichten.de logoAkers Biosciences Announces Q1 2017 Earnings / Significant Cost Reductions and Progress Towards Breakeven
www.finanznachrichten.de - May 16 at 3:28 PM
finance.yahoo.com logoInvestor Network: Akers Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - May 16 at 3:28 PM
marketwatch.com logoAkers Biosciences narrows loss, but revenue falls - MarketWatch
www.marketwatch.com - May 16 at 7:08 AM
finance.yahoo.com logoAkers Biosciences Announces Q1 2017 Earnings
finance.yahoo.com - May 16 at 7:08 AM
finance.yahoo.com logoAkers Biosciences Announces Conference Call to Discuss Q1 2017 Earnings
finance.yahoo.com - May 12 at 3:58 PM
finance.yahoo.com logoAkers Biosciences Updates on Akers Wellness(TM) Tests - Yahoo Finance
finance.yahoo.com - April 24 at 3:29 PM
marketwatch.com logoAkers Biosciences to Commercialize Heparin PF4 Rapid Test in Puerto Rico - MarketWatch
www.marketwatch.com - April 11 at 8:18 AM
finance.yahoo.com logoAkers Biosciences Reports Earnings for Fiscal Year 2016
finance.yahoo.com - April 11 at 8:18 AM
finance.yahoo.com logoAkers Biosciences Reports Preliminary Unaudited Earnings Highlights for Fiscal Year 2016 - Yahoo Finance
finance.yahoo.com - March 30 at 3:50 PM
finance.yahoo.com logoAkers Biosciences Begins Selling Rapid Cholesterol Test through Distribution Agreement with First Check - Yahoo Finance
finance.yahoo.com - March 28 at 3:25 PM
finance.yahoo.com logo2 US Patent Approvals Driving Stocks Higher on Thursday
finance.yahoo.com - February 16 at 3:29 PM
marketwatch.com logoAkers Biosciences Announces Closing of Public Offering - MarketWatch
www.marketwatch.com - January 14 at 3:25 PM
streetinsider.com logoForm 8-K Akers Biosciences Inc For: Jan 13 - StreetInsider.com
www.streetinsider.com - January 13 at 3:49 PM
bizjournals.com logoSouth Jersey maker of rapid screening tests plans $2M stock sale
www.bizjournals.com - January 11 at 3:43 PM
finance.yahoo.com logoAkers Biosciences Announces Pricing of Public Offering of 1667000 Shares and 833500 Warrants - Yahoo Finance
finance.yahoo.com - January 9 at 8:39 PM
finance.yahoo.com logoAkers Biosciences Signs 3-year Agreement with GNYHA Services for Heparin PF4 Rapid Test - Yahoo Finance
finance.yahoo.com - December 23 at 1:30 AM
marketwatch.com logoAkers Biosciences halves loss; revenue up 262%
www.marketwatch.com - November 14 at 12:09 PM
finance.yahoo.com logoAkers Biosciences OxiCheck Study Results Positive, Stock Up
finance.yahoo.com - October 3 at 3:22 PM
finance.yahoo.com logoAkers Biosciences Chlamydia Rapid Test Results Positive
finance.yahoo.com - July 1 at 9:33 AM
lse.co.uk logoAkers Bio Share Chat
www.lse.co.uk - June 27 at 8:09 AM
finance.yahoo.com logoAkers' Loss Widens in 2015, Revenues Deteriorate Y/Y
finance.yahoo.com - March 30 at 10:46 AM
finance.yahoo.com logoWhat Awaits Akers Biosciences (AKER) in Q4 Earnings?
finance.yahoo.com - March 28 at 9:10 AM
finance.yahoo.com logoAkers Biosciences' Protein Preparation Gets Patent Cover
finance.yahoo.com - March 24 at 10:10 AM

Social

Social activity is not available for this stock.

Chart

Akers Biosciences (AKR) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff